SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, BSTC, MYOK, and CBMG Mergers

Under the terms of the agreement Concho Resources shareholders will receive 1.46 shares of ConocoPhillips common stock per share.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, October 21, 2020

Information

Tags:

Financial markets, Financial economics, Stock market, Corporate finance, Finance, Equity securities, Concha, Shareholder, Stock, ConocoPhillips, Common stock

Geotags:

Wilmington, De, Us

Organisation:

RIGRODSKY & LONG, P.A.

Summary

Key Points:

Under the terms of the agreement Concho Resources shareholders will receive 1.46 shares of ConocoPhillips common stock per share.
To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-concho-resources-inc .
Under the terms of the agreement, BioSpecifics Technologies shareholders will receive $88.50 in cash per share.
You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

WILMINGTON, Del., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

Concho Resources Inc. (NYSE: CXO) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips. Under the terms of the agreement Concho Resources’ shareholders will receive 1.46 shares of ConocoPhillips’ common stock per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-concho-resources-inc.

BioSpecifics Technologies Corp. (NASDAQ GM: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics Technologies’ agreement to be acquired by Endo International plc. Under the terms of the agreement, BioSpecifics Technologies’ shareholders will receive $88.50 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-biospecifics-technologies-corp.

MyoKardia, Inc. (NASDAQ GS: MYOK) regarding possible breaches of fiduciary duties and other violations of law related to MyoKardia’s agreement to be acquired by Bristol-Myers Squibb Company. Under the terms of the agreement, MyoKardia’s shareholders will receive $225.00 in cash per share. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-myokardia-inc.

Cellular Biomedicine Group, Inc. (NASDAQ GS: CBMG) regarding possible breaches of fiduciary duties and other violations of law related to Cellular Biomedicine’s agreement to be acquired by a consortium headed by Bizuo (Tony) Liu. Under the terms of the agreement Cellular Biomedicine’s shareholders will receive $19.75 per share in cash. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-cellular-biomedicine-group-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com